Hecht, J. R., Elez, E., Eng, C., Gibbs, P., Seligmann, J. F., Xu, R., Yamaguchi, K., Wang, C., Teng, H. W., Trani, L., Wortman-Vayn, H., Jiang, Z., Diorio, B., Lorenzini, P. A., Baudelet, C., Sethi, S. N., Baig, M., Cremolini, C. (2025). OrigAMI-3: A randomized, phase 3 study of amivantamab plus FOLFIRI vs cetuximab or bevacizumab plus FOLFIRI in participants with recurrent, unresectable, or metastatic
            <i>RAS/BRAF</i>
            wild-type colorectal cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps3638